The UK market has been navigating choppy waters, with the FTSE 100 recently closing lower due to weak trade data from China, highlighting global economic uncertainties. In such a climate, investors often seek opportunities in less conventional areas like penny stocks, which despite their outdated moniker, can still represent smaller or emerging companies with potential for growth. By focusing on those with solid financial foundations and promising business models, investors may find attractive prospects among these lesser-known entities.
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Amcomri Group plc operates in the engineering and industrial manufacturing sectors within the United Kingdom, with a market capitalization of £107.25 million.
Operations: The company generates revenue through its B2B Manufacturing segment, which accounts for £33.76 million, and its Embedded Engineering segment, contributing £37.18 million.
Market Cap: £107.25M
Amcomri Group plc has demonstrated strong financial performance, with recent earnings growth of 187.4% and net income rising to £3.01 million from £1.05 million the previous year. The company’s revenue reached £70.94 million, supported by its B2B Manufacturing and Embedded Engineering segments. Amcomri’s debt is well covered by operating cash flow at 43%, and its short-term assets exceed both short-term and long-term liabilities, indicating solid financial health. However, its Return on Equity remains low at 12.5%. The management team is experienced, though the board of directors lacks tenure stability with an average tenure of just 1.5 years.
AIM:AMCO Financial Position Analysis as at May 2026
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Creo Medical Group PLC focuses on the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom, with a market cap of £63.68 million.
Operations: Creo Medical Group PLC has not reported any specific revenue segments.
Market Cap: £63.68M
Creo Medical Group PLC, with a market cap of £63.68 million, is currently unprofitable but has shown significant progress in reducing its losses over the past five years. The company reported sales of £6 million for 2025, up from £4 million the previous year, and achieved a net income of £5.3 million compared to a substantial loss previously. Creo’s innovative products like MicroBlate Fine and SpydrBlade Flex are gaining traction in key markets such as the US, enhancing its potential for future revenue growth. Despite high share price volatility recently, Creo’s seasoned management team supports strategic advancements in medical device innovation.
AIM:CREO Debt to Equity History and Analysis as at May 2026
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Zotefoams plc, along with its subsidiaries, manufactures, distributes, and sells polyolefin foams across Europe, the Middle East, Africa, North America, and Asia with a market cap of £206.28 million.
Operations: The company’s revenue is derived from the following segments: £4.23 million from Asia, £123.95 million from EMEA, £30.08 million from North America, and £0.22 million from Mucell Extrusion LLC (MEL).
Market Cap: £206.28M
Zotefoams plc, with a market cap of £206.28 million, has recently transitioned to profitability, reporting a net income of £22.64 million for 2025 compared to a loss the previous year. The company’s revenue increased to £158.49 million from £147.79 million, driven by strong performance across its geographical segments. Zotefoams is trading at an attractive valuation relative to peers and industry standards while maintaining stable weekly volatility and satisfactory debt levels with well-covered interest payments by EBIT (13.7x). Despite having an inexperienced management team and board, the company has not diluted shareholders recently and offers a dividend yield increase as of April 2026.
LSE:ZTF Debt to Equity History and Analysis as at May 2026 Where To Now?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:AMCO AIM:CREO and LSE:ZTF.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com